Earlier this year, Catalent announced the addition of commercial spray drying capabilities at its Winchester, KY facility.  Combined with the Haverhill, U.K. facility, customers can now access:

 

• End-to-end accelerated spray drying solutions from early development through clinical supply and scale-up commercial finished dose form manufacturing
• State-of-the-art facilities in the United States and Europe
• Early-phase spray drying development sites in San Diego, CA and Nottingham, U.K.

 

Learn how our newest commercial spray drying investments will help your molecules from early development to downstream dose form manufacturing.

Lipid formulation and spray-dried dispersions are widely used, and proven technologies to overcome bioavailability challenges for poorly soluble molecules. For selecting the most suitable formulation technologies in early-phase development, formulation scientists regard efficacy, safety, bioavailability and stability as their top priorities. However, an early-phase formulation strategy should also consider scale-up and manufacturing challenges that may arise later in development.

If bioavailability and manufacturing challenges are not addressed in early development, the cost and overall timeline of the project may be negatively impacted. Therefore, developing a bioavailable formulation that is easy to scale-up with superior dose uniformity is imperative for a product’s success.